FRANK FITZPATRICK, CFO of Balchem Corporation, bought 14,000 shares of Balchem (Stock Symbol: BCPC) at $11.87 per share for a total amount of $166,000 on January 15, 2014.
Balchem Corporation is based in New Hampton, NY.
On Dec. 13th 2013, Balchem Corporation (BCPC) announced that its Board of Directors has declared a dividend on its shares of common stock equal to $0.26 per share, payable on January 21, 2014 to holders of record on December 23, 2013. This dividend reflects an 18% increase over the prior year cash dividend.
On Nov. 5th 2013, Balchem announced its latest quarter results. For the quarter ended September 30, 2013, the company achieved record quarterly net sales of $87.6 million, which is an increase of approximately 16.6% above the $75.1 million result of the prior year comparative quarter. Record quarterly net earnings were achieved of $11.7 million, an increase of $0.8 million, or 7.2% as compared with the same period last year. The $11.7 million generated diluted net earnings of $0.38 per common share versus $0.36 per common share for the prior year comparable period, an increase of 5.6%.
According to Capital IQ, Balchem has a market cap of $1.71 billion, an enterprise value of $1.51 billion, and trailing 12 month revenues of $336 million.
Balchem Corporation is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical and medical sterilization industries. The Company operates in three segments: Specialty Products, Food, Pharma & Nutrition and Animal Nutrition & Health. The Food, Pharma & Nutrition (FPN) segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients. The Company’s Specialty Products segment operates in industry as ARC Specialty Products. Ethylene oxide, at the 100% level, is sold as a sterilant gas, primarily for use in the health care industry. The Company’s Animal Nutrition & Health segment provides the animal nutrition and health markets with products derived from the Company’s microencapsulation, chelation, and basic choline chloride technologies.
Francis Fitzpatrick’s most recent annual compensation from Balchem is a salary of $356,000 and $345,407 in options for a total of $815,000. Mr. Fitzpatrick is 53 years old.
According to the biography, Mr. Francis J. Fitzpatrick, CPA, is Chief Financial Officer, Treasurer, Assistant Secretary of Balchem Corporation. He has been the Chief Financial Officer of the Company since January 2004 and Treasurer of the Company since June 2003, and was Controller of the Company from April 1997 to January 2004. He was Director of Financial Operations/Controller of Alliance Pharmaceutical Corp., a pharmaceuticals company, from September 1989 through March 1997.
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .
About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.